Yazar "Sahebkar, Amirhossein" seçeneğine göre listele
Listeleniyor 1 - 20 / 34
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe A Review on Biosensors for Quantification of MCP-1 as a Potential Biomarker in Diseases(Wiley, 2025) Bahaabadi, Zahra Jamalizadeh; Javid-Naderi, Mohammad Javad; Kesharwani, Prashant; Karav, Sercan; Sahebkar, AmirhosseinMonocyte chemoattractant protein-1 (MCP-1) as a chemokine is essential for inflammation-related processes. It regulates immunological responses and cell migration, which contribute to inflammation. Many disorders are exacerbated by this chemokine, which attracts or grows other inflammatory cells, including monocytes/macrophages, at the site of infection or tissue injury. The elevated concentrations of MCP-1 are associated with the pathogenesis of many diseases, such as cancer, cardiovascular disease, kidney disease, and neuroinflammatory disease. Therefore, monitoring this inflammatory biomarker in the body has been recommended and strongly advised to make an accurate diagnosis and prognosis. Although MCP-1 is of great importance in disease processes, few biosensing approaches are specifically designed to detect this molecule. These are often electrochemical and optical techniques. Rapid and accurate diagnosis of inflammatory diseases by identifying biomarkers has had a great effect on the advancement of biosensors. Improved biosensor technology expansion prevents excessive prices and low sensitivity, enabling quick and correct diagnosis and tracking of disease processes. This review will concentrate on the biological functions of MCP-1, its significance in different disorders, and the features and applications of biosensors designed for MCP-1 detection and quantification.Öğe Advances in Apolipoprotein-A4 Biosensing Assays for Depression Diagnosis(Taylor & Francis Inc, 2025) Bahaabadi, Zahra Jamalizadeh; Karav, Sercan; Sahebkar, AmirhosseinApolipoprotein-A4 (Apo-A4) is a plasma protein that plays a role in various physiological and behavioral-emotional reactions when faced with stress. Studies have shown a close relationship between Apo-A4 and the onset of depression and its symptoms. However, there is currently no reliable laboratory approach to confirm the diagnosis of depression. Therefore, the development of a precise and effective technique to assess Apo-A4 might help in the early detection and screening of depression and other related psychiatric diseases, as well as in tracking and managing the course of treatment. As technology advances, biosensors have become quick, accurate, and sensitive tools for personal care and illness diagnosis. Biosensors for measuring and detecting Apo-A4 levels have recently been designed. These studies emphasized the development of accurate and sensitive diagnostic and measurement techniques. This review attempts to give a general overview of the role of Apo-A4 in depression and introduce established biosensors for its detection and measurement.Öğe Beyond the Hayflick limit: How microbes influence cellular aging(Elsevier Ireland Ltd, 2025) Abavisani, Mohammad; Faraji, Saba; Ebadpour, Negar; Karav, Sercan; Sahebkar, AmirhosseinCellular senescence, a complex biological process resulting in permanent cell-cycle arrest, is central to aging and age-related diseases. A key concept in understanding cellular senescence is the Hayflick Limit, which refers to the limited capacity of normal human cells to divide, after which they become senescent. Senescent cells (SC) accumulate with age, releasing pro-inflammatory and tissue-remodeling factors collectively known as the senescence-associated secretory phenotype (SASP). The causes of senescence are multifaceted, including telomere attrition, oxidative stress, and genotoxic damage, and they extend to influences from microbial sources. Research increasingly emphasizes the role of the microbiome, especially gut microbiota (GM), in modulating host senescence processes. Beneficial microbial metabolites, such as short-chain fatty acids (SCFAs), support host health by maintaining antioxidant defenses and reducing inflammation, potentially mitigating senescence onset. Conversely, pathogenic bacteria like Pseudomonas aeruginosa and Helicobacter pylori introduce factors that damage host DNA or increase ROS, accelerating senescence via pathways such as NF-?B and p53-p21. This review explores the impact of bacterial factors on cellular senescence, highlighting the role of specific bacterial toxins in promoting senescence. Additionally, it discusses how dysbiosis and the loss of beneficial microbial species further contribute to age-related cellular deterioration. Modulating the gut microbiome to delay cellular senescence opens a path toward targeted anti-aging strategies. This work underscores the need for deeper investigation into microbial influence on aging, supporting innovative interventions to manage and potentially reverse cellular senescence. © 2025 Elsevier B.V.Öğe Curcumin-based nanofibers: A promising approach for cancer therapy(Elsevier Gmbh, 2025) Rahiman, Niloufar; Kesharwani, Prashant; Karav, Sercan; Sahebkar, AmirhosseinNanofibers are among the promising platforms for efficient delivery of drugs (both hydrophilic and hydrophobic) through harnessing polymers with different natures as their base. Hydrophobic low-solubility agents such as curcumin could be incorporated in various types of electrospun nanofibers for different aims in drug delivery, such as enhancing its solubility, making this agent sustained release with improved pharmacological efficacy. Through using this nanoplatform, curcumin may become more bioavailable and more efficcious in the field of cancer therapy as well as tissue engineering and wound healing for local delivery of this anti-inflammatory and antioxidant agent. In this review, the characteristics of curcumin-loaded nanofibers, their targeting potential or stimuli-responsiveness accompanied with therapeutic anti-cancerous applications of them (mostly in local application) are securitized. These nanofibers follow the aim of enhancing curcumin's therapeutic effectiveness and release profile. We laso elaborate on the mechanisms of action through which curcumin exerts its effect on various cancerous cells after its incorporation in various types of nanofibers which have been prepared by exploiting different polymers.Öğe Decoy oligodeoxynucleotides targeting STATs in non-cancer gene therapy(Elsevier, 2025) Mahjoubin-Tehran, Maryam; Rezaei, Samaneh; Kesharwani, Prashant; Karav, Sercan; Sahebkar, AmirhosseinThe Signal Transducer and Activator of Transcription (STAT) protein family is crucial for organizing the epigenetic configuration of immune cells and controlling various fundamental cell physiological functions including apoptosis, development, inflammation, immunological responses, and cell proliferation and differentiation. The human genome has seven known STAT genes, named 1, 2, 3, 4, 5a, 5b, and 6. Aberrant activation of STAT signaling pathways is associated with many human disorders, particularly cardiovascular diseases (CVDs), making these proteins promising therapeutic targets. Improved understanding of altered and pathological gene expression and its role in the pathophysiology of various hereditary and acquired disorders has enabled the development of novel treatment approaches based on gene expression modulation. One such promising development is the oligodeoxynucleotide decoy method, which may allow researchers to specifically influence gene activation or repression. Various oligodeoxynucleotide decoys target STATs and affect the expression of its downstream genes. We summarized cell culture and preclinical research, which evaluated the effects of oligodeoxynucleotide decoys target STATs in different types of non-cancer illnesses.Öğe Decoy oligodeoxynucleotides: A promising therapeutic strategy for inflammatory skin disorders(Elsevier Science Inc, 2024) Mahjoubin-Tehran, Maryam; Rezaei, Samaneh; Karav, Sercan; Kesharwani, Prashant; Sahebkar, AmirhosseinChronic inflammatory skin conditions such as psoriasis and atopic dermatitis (AD) impose a significant burden on both the skin and the overall well-being of individuals, leading to a diminished quality of life. Despite the use of conventional treatments like topical steroids, there remains a need for more effective and safer therapeutic options to improve the lives of patients with severe skin conditions. Molecular therapy has emerged as a promising approach to address disorders such as atopic dermatitis, psoriasis, and contact hypersensitivity. One strategy to counteract the disease processes involves targeting the transcriptional process. A novel form of gene therapy utilizes double-stranded oligodeoxynucleotides (ODNs), also known as decoys, that contain cis-elements. By introducing these decoy ODNs through transfection, the cis-trans interactions are disrupted, leading to the inhibition of trans-factors from binding to the intrinsic cis-elements and thus regulating gene expression. In this review, we have summarized studies investigating the therapeutic effects of decoy ODNs on inflammatory skin diseases. Various transcription factors, including NF-kB, STAT6, HIF-1 alpha/STAT5, STAT1, and Smad, have been targeted and inhibited using designed decoy ODNs for the treatment of atopic dermatitis, psoriasis, hypertrophic scarring, and contact hypersensitivity. The findings of these studies confirm the significant potential of the decoy approach in the treatment of inflammatory skin diseases.Öğe Enhancing curcumin's efficacy with zinc oxide nanoparticles: A dynamic duo in combatting disease(Elsevier, 2025) Nejabat, Mojgan; Hadizadeh, Farzin; Karav, Sercan; Kesharwani, Prashant; Sahebkar, AmirhosseinThe combination of Zinc Oxide Nanoparticles (ZnO NPs) and Curcumin (Cur) has garnered significant attention due to its therapeutic potential (e. g., cancer treatment, wound healing, and antioxidant applications). CUR has been highly regarded as a natural compound with pharmacological properties such as anticancer, antimicrobial, and antioxidant effects; however, its clinical applications are limited due to its low solubility and bioavailability. In this review, the potentials of CUR and ZnO NPs in the case of biomedical applications were taken into consideration. There have been many attempts to integrate ZnO NPs and CUR for enhancing the mentioned drawbacks of CUR. The effectiveness of ZnO-Cur (CUR/ZnO NPs) nanocomposites, particularly in cancer therapies has been very promising. These nanocomposites exhibit selective toxicity towards cancer cells, with their pH-sensitive release mechanism proving advantageous in targeting the acidic tumor microenvironment. In addition to these effects, CUR/ZnO NPs have antioxidant activity, induce apoptosis in cancer cells, and promote wound healing. The use of ZnO and ZnO-Cur composites led to notable improvements across various applications such as osteoblast viability increased by approximately 60%, Cur release improved by 150%, and osteosarcoma inhibition enhanced by 300%. In agricultural use, ZnO NPs increased silybin content and plant yield while sperm cryopreservation studies showed improved post-thaw quality with ZnO-Cur by measurable margins, significantly. The role of ZnO in boosting Cur bioavailability, therapeutic efficacy, and targeted delivery potential have been confirmed in several studies. However, there are many unsolved challenges such as scalability, cytotoxicity data, and toxicity at higher concentrations that need to be addressed.Öğe Exosome/Extracellular Vesicles-Based Therapeutics in Alzheimer's Disease: Neuroprotective Roles and Future Perspectives(Springernature, 2025) Ebadpour, Negar; Abavisani, Mohammad; Karav, Sercan; Kesharwani, Prashant; Sahebkar, AmirhosseinAlzheimer's disease (AD), a progressive neurodegenerative disorder, is marked by memory loss, cognitive decline, and characteristic pathological features including beta-amyloid (A beta) plaques, tau tangles, and neuroinflammation. Despite extensive research, effective therapies remain elusive. Exosome/EVs-based therapeutics have emerged as a promising avenue for AD treatment. Neuron-derived exosomes/extracellular vesicles (EVs) (NDEs) and stem cell-derived exosomes/EVs exhibit neuroprotective effects by promoting A beta degradation, modulating tau pathology, and reducing inflammation. Notably, NDEs carry insulin-degrading enzyme (IDE) and cellular prion proteins (PrPC), aiding A beta clearance. However, exosomes also present challenges, such as the potential propagation of pathogenic tau and complement-mediated neurotoxicity. Neural and mesenchymal stem cell-derived exosomes further demonstrate therapeutic efficacy by altering amyloid precursor protein processing and activating PI3K/Akt/mTOR signaling to reduce AD pathology. Despite these advancements, clinical translation requires a deeper understanding of exosome/EVs biology, improved isolation techniques, and personalized strategies. Continued research may establish exosomes as a transformative approach in AD therapy.Öğe Exploring the antioxidant properties of semaglutide: A comprehensive review(Elsevier Science Inc, 2024) Yaribeygi, Habib; Maleki, Mina; Forouzanmehr, Behina; Kesharwani, Prashant; Jamialahmadi, Tannaz; Karav, Sercan; Sahebkar, AmirhosseinPatients with diabetes commonly experience an aberrant production of free radicals and weakened antioxidative defenses, making them highly susceptible to oxidative stress development. This, in turn, can induce and promote diabetic complications. Therefore, utilizing antidiabetic agents with antioxidative properties can offer dual benefits by addressing hyperglycemia and reducing oxidative damage. Semaglutide, a recently approved oral form of glucagon-like peptide-1 (GLP-1) analogues, has shown potent antidiabetic effects. Additionally, recent studies have suggested that it possesses antioxidative properties. However, the exact effects and the molecular pathways involved are not well understood. In this review, we present the latest findings on the antioxidative impacts of semaglutide and draw conclusions about the mechanisms involved.Öğe Impact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities(Springer Heidelberg, 2024) Askarizadeh, Fatemeh; Karav, Sercan; Jamialahmadi, Tannaz; Sahebkar, AmirhosseinStatins are widely utilized to reduce cholesterol levels, particularly in cardiovascular diseases. They interface with cholesterol synthesis by inhibiting the 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase enzyme. Besides their primary effect, statins demonstrate anti-inflammatory and immune-modulating properties in various diseases, highlighting the pleiotropic effect of these drugs. The CD40:CD40L signaling pathway is considered a prominent inflammatory pathway in multiple diseases, including autoimmune, inflammatory, and cardiovascular diseases. The findings from clinical trials and in vitro and in vivo studies suggest the potential anti-inflammatory effect of statins in modulating the CD40 signaling pathway and downstream inflammatory mediator. Accordingly, as its classic ligand, statins can suppress immune responses in autoimmune diseases by inhibiting CD40 expression and blocking its interaction with CD40L. Additionally, statins affect intracellular signaling and inhibit inflammatory mediator secretion in chronic inflammatory diseases like asthma and autoimmune disorders such as myasthenia gravis, multiple sclerosis, systemic lupus erymanthus, and cardiovascular diseases like atherosclerosis. However, it is essential to note that the anti-inflammatory effect of statins may vary depending on the specific type of statin used. In this study, we aim to explore the potential anti-inflammatory effects of statins in treating inflammatory diseases by examining their role in regulating immune responses, particularly their impact on the CD40:CD40L signaling pathway, through a comprehensive review of existing literature.Öğe Interleukin-1? biosensors: Emerging analytical approaches for precision diagnostics(Elsevier, 2026) Bahaabadi, Zahra Jamalizadeh; Mahmoudi, Ali; Karav, Sercan; Kesharwani, Prashant; Sahebkar, AmirhosseinInterleukin-1 beta (IL-1 beta) is a pro-inflammatory cytokine secreted by activated immune cells that plays a central role in regulating inflammatory responses and immune signaling. Aberrant IL-1 beta expression is strongly associated with numerous pathological conditions, including autoimmune and inflammatory diseases, cancers, and allergic disorders. Accurate and sensitive quantification of IL-1 beta is therefore critical for early diagnosis, disease monitoring, and therapeutic evaluation. Over the past two decades, significant progress has been made in developing biosensors capable of rapid, precise, and cost-effective IL-1 beta detection. This review critically summarizes recent advancements in electrochemical, optical, and electronic biosensing platforms designed for IL-1 beta measurement. Emphasis is placed on the analytical performance, transduction mechanisms, biorecognition elements, and material innovations that underpin these sensor technologies. Literature published between 2000 and 2024 was systematically analyzed to assess design trends, detection limits, and translational applicability. With continuous improvements in sensitivity, selectivity, and miniaturization, IL-1 beta biosensors are poised to transition from laboratory prototypes to clinically deployable diagnostic tools. These advances highlight the growing potential of biosensor technology in precision medicine and real-time immunological monitoring.Öğe Lerodalcibep: Another Crucial Addition to the Dyslipidaemia Arsenal(Imr Press, 2025) Sahebkar, Amirhossein; Karav, Sercan; Almahmeed, Wael; Jamialahmadi, Tannaz[No abstract available]Öğe Lipid nanoparticle-based delivery of small interfering RNAs: New possibilities in the treatment of diverse diseases(Pergamon-Elsevier Science Ltd, 2025) Askarizadeh, Anis; Vahdat-Lasemi, Fatemeh; Karav, Sercan; Kesharwani, Prashant; Sahebkar, AmirhosseinRNA interference (RNAi) is a well-known post-transcriptional gene-silencing mechanism that has garnered significant attention as a potentially powerful therapeutic procedure for combating recalcitrant diseases. Small interfering RNA (siRNA) as an effective RNAi tool mediates gene silencing pathway by mRNA degradation in cells and presents a unique strategy for the treatment of rebellious diseases. However, the low stability and suboptimal pharmacokinetic behavior of naked siRNAs have made it necessary to employ a delivery vehicle to protect siRNA against degradation and allow for its intracellular delivery. Among a plethora of available delivery platforms, lipid nanoparticles (LNPs) have received significant research attention and are currently recognized as the most advanced delivery system for RNA-based therapeutic agents. This is exemplified by the approval of Onpattro (R) for treating amyloidosis in the US and the European Union in 2018, as well as the development of COVID-19 mRNA vaccines. This review aims to provide a comprehensive evaluation of the potential effectiveness of lipid-based nanoparticles as a delivery system for siRNA in treating a wide array of diseases.Öğe Mechanistic insights into postbiotics as therapeutic agents in type 2 diabetes management(Springer, 2025) Ebadpour, Negar; Faraji, Navid; Abavisani, Mohammad; Karav, Sercan; Sahebkar, AmirhosseinThe rising prevalence of type 2 diabetes mellitus (T2DM) alongside its associated morbidity and complications underscores the need for adjunctive therapies beyond glycemic control and lifestyle modification. Emerging evidence implicates gut microbiota-derived metabolites in the modulation of host energy homeostasis. One of these metabolites, postbiotics-the bioactive substances created during the fermentation of probiotics-have now become a promising therapeutic. Postbiotics, which contain short-chain fatty acids (SCFAs), exopolysaccharides (EPS), peptidoglycans, bacteriocins, vitamins, and neurotransmitters, have numerous mechanisms that regulate glucometabolism, improve insulin sensitivity, and are able to attenuate systemic inflammation. These compounds are able to regulate insulin receptor signaling and hepatic glucose production by modulating such key metabolic pathways as glycolysis and gluconeogenesis. Based on the previous preclinical and clinical evidence, postbiotic compounds exhibit mechanistic plausibility as adjunct therapies for T2DM. However, due to heterogeneity in patient microbiomes and a lack of standardized formulations that limit current applicability, further investigations are required. Future investigations should focus on dose-finding, long-term safety, and stratification of responders based on microbial and metabolic phenotypes. This review explores the role of postbiotics in T2DM from a mechanistic point of view, highlights their clinical significance in T2DM management, and discusses the next avenue to improve the therapeutic approaches.Öğe Modulation of the ubiquitin-proteasome system by curcumin: Therapeutic implications in cancer(2025) Torghabe, Shima Yahoo; Alavi, Parisa; Rostami, Sara; Davies, Neal M.; Kesharwani, Prashant; Karav, Sercan; Sahebkar, AmirhosseinBy the ubiquitin-proteasomes, cellular proteins are structurally degraded and turnover. Many essential functions and regulations of cells are regulated and controlled by these proteins. Recent studies indicated that many cancer types have been associated with aberrations in the ubiquitination pathway, which involves three enzymatic steps. Dietary phytochemicals have been identified as having the potential to inhibit carcinogenesis recently. As part of this group of phytochemicals, curcumin can play a crucial role in suppressing carcinogenesis by changing many reactions affected by the ubiquitin-proteasome pathway. Due to its ability to change some biological processes such as NF-κB, inhibit some cyclins, and induce apoptosis, it can be used as a drug in cancer treatment.Öğe Nano-phytoconstituents: Recent advances, regulatory insights, challenges, and future horizons(Elsevier, 2025) Beygi, Mohammad; Oroojalian, Fatemeh; Karav, Sercan; Kesharwani, Prashant; Sahebkar, AmirhosseinPhytoconstituents possess therapeutic potency in human diseases, including antioxidant, antitumor, antiinflammatory, and anti-microbial impacts, as well as cardioprotective and neuroprotective capabilities. Nonetheless, they suffer from shortcomings like low solubility and bioavailability, fast degradation upon administration, and elevated doses required to exert therapeutic effects, culminating in potential adverse effects. As a solution to these, nanoscale drug delivery systems (DDSs) such as polymeric nanoparticles (NPs), lipid-based NPs, protein-based NPs, etc. are currently devised to realize intended goals in herbal medicine, which critically are sustained release and targeted delivery of phytomedicines to affected sites. Current DDSs are formulated to encapsulate diverse phytochemicals, including curcumin, berberine, resveratrol, quercetin, baicalin, and rosmarinic acid. The ultimate nanoassembly affords superior properties such as protracted circulation time, sustained release, site-specific delivery, synergistic effects (with antitumor agents), and measurable diseasealleviating effects. This article covers recent progress in nanophytomedicines and explores how DDSs can enrich the therapeutic properties of these phytochemicals. Further, the present article covers the regulatory aspects and ethical issues to be reflected when devising such DDSs, as well as the current standing of nanophytoconstituents in clinical trials.Öğe Nanozymes: A novel approach to upgrade atherosclerosis treatment(Elsevier Gmbh, 2025) Mahjoubin-Tehran, Maryam; Kesharwani, Prashant; Alamahmeed, Wael; Karav, Sercan; Sahebkar, AmirhosseinAtherosclerosis has become a global health concern, contributing to the rise in cardiovascular diseases and causing significant morbidity and disability. The development of atherosclerosis begins with the accumulation of low-density lipoprotein (LDL) in the subendothelial space. As LDL becomes trapped in the arterial walls, reactive oxygen species (ROS) are generated, resulting in oxidative stress, impaired endothelial function, and oxidative modification of the retained LDL, forming oxidized LDL (ox-LDL). The oxidation of LDL to form ox-LDL is considered one of the most important factors in the development of atherosclerosis. Recently, there has been a growing interest in nanomaterials with enzyme-like characteristics called nanozymes in the field of biomedicine. The use of nanozymes has become increasingly popular because they offer solutions to the limitations associated with natural enzymes, including high costs, low stability, and challenging storage requirements. Nanozymes with anti-oxidative activities, such as catalase-, SOD-, and GPx-like nanozymes, have been extensively studied for various disease therapies, including atherosclerosis. Furthermore, nanozymes can be designed to have multiple enzyme-like activities. In this review, we aim to summarize studies that have used nanozymes as a therapeutic approach for the treatment of atherosclerosis. The results of this study have shown that nanozymes have a significant impact in reducing atherosclerotic plaques in ApoE- /- mice. This effect is mainly achieved through ROS scavenging, which leads to the suppression of foam cell formation and inflammation.Öğe Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms(Pergamon-Elsevier Science Ltd, 2025) Yaghmayee, Shayan; Moazzeni, Atefeh Sadat; Jamialahmadi, Tannaz; Karav, Sercan; Yaribeygi, Habib; Kesharwani, Prashant; Sahebkar, AmirhosseinNeuronal injury is a common complication in patients with diabetes. These injuries include a wide range of neurobehavioral complications that significantly reduce the neuronal network efficiency and quality of life in affected individuals. Currently, diabetes-induced neuronal complications are a major global health challenge, and many studies have been performed to prevent or slow their progression. Semaglutide is a novel form of glucagon-like peptide-1 (GLP-1) agonist agents that has recently been approved for diabetic patients to normalize glucose metabolism. However, some evidence indicates that it has extra-glycemic effects in some tissues as well as in the central nervous system. This evidence suggests that semaglutide can suppress some pathophysiological pathways involved in diabetes-induced neuronal complications and thus improve neuronal network efficiency. However, there is limited evidence to support all the pathways involved in mediating these benefits. In the current review, we aim to present the latest clinical and experimental findings on the possible benefits of semaglutide on major neuronal complications and to determine the possible molecular mechanisms involved.Öğe Nutritional factors and physical frailty: Highlighting the role of functional nutrients in the prevention and treatment(Elsevier Ireland Ltd, 2024) Ziaei, Rahele; Shahdadian, Farnaz; Bagherniya, Mohammad; Karav, Sercan; Sahebkar, AmirhosseinPhysical frailty, an age-related decline in the physiological capacity and function of various organs, is associated with higher vulnerability to unfavorable health outcomes. The mechanisms proposed for physical frailty including increased inflammation and oxidative stress are closely related to nutritional status. In addition to traditional nutritional factors such as protein malnutrition and nutrient deficiencies, emerging evidence has focused on the role of functional nutrients including polyphenols, carotenoids, probiotics, prebiotics, omega-3 long-chain polyunsaturated fatty acids (n-3 PUFAs), (3-hydroxy-(3-methylbutyrate (HMB), coenzyme Q10 (CoQ10), and L-carnitine in modifying the risk of physical frailty syndrome. Although several clinical trials have suggested the beneficial effects of supplementation with polyphenols, HMB, and prebiotics on frailty indices, the current evidence is still not robust to support recommendations on the routine clinical use of such functional nutrients for the management of frailty. Similarly, the association between CoQ10 and frailty was mainly assessed in observational studies, and more randomized controlled trials are needed in this regard. A limited number of studies have reported the beneficial effect of L-carnitine supplementation on frailty indices. Since carnitine is mainly found in skeletal muscle and its measurement is thus challenging due to ethical constraints, it is necessary to examine the effect of different doses of L-carnitine on frailty and its indices in future studies. A large number of interventional studies evaluated the impact of n-3 PUFA supplementation on physical frailty in the elderly and many of them reported improved physical performance following supplementation, especially when combined with resistance training programs. Although promising findings from experimental and observational studies have been reported on functional nutrients, high-quality evidence from randomized controlled trials as well as detailed mechanistic studies are still required to affirm their role in the prevention and/or treatment of physical frailty. This review aims to describe the current state of research on functional nutrients that may modify the development or prognosis of frailty syndrome.Öğe Overcoming antibiotic resistance: the potential and pitfalls of drug repurposing(Taylor & Francis Ltd, 2024) Abavisani, Mohammad; Khoshrou, Alireza; Eshaghian, Souzan; Karav, Sercan; Sahebkar, AmirhosseinSince its emergence shortly after the discovery of penicillin, antibiotic resistance has escalated dramatically, posing a significant health threat and economic burden. Drug repositioning, or drug repurposing, involves identifying new therapeutic applications for existing drugs, utilising their established safety profiles and pharmacological data to swiftly provide effective treatments against resistant pathogens. Several drugs, including otilonium bromide, penfluridol, eltrombopag, ibuprofen, and ceritinib, have demonstrated potent antibacterial activity against multidrug-resistant (MDR) bacteria. These drugs can disrupt biofilms, damage bacterial membranes, and inhibit bacterial growth. The combination of repurposed drugs with conventional antibiotics can reduce the required dosage of individual drugs, mitigate side effects, and delay the development of resistance, making it a promising strategy against MDR bacteria such as Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli. Despite its promise, drug repurposing faces challenges such as potential off-target effects, toxicity, and regulatory and intellectual property issues, necessitating rigorous evaluations and strategic solutions. This article aims to explore the potential of drug repurposing as a strategy to combat antibiotic resistance, examining its benefits, challenges, and future prospects. We address the legal, economic, and practical challenges associated with repurposing existing drugs, highlight successful examples, and propose solutions to enhance the efficacy and viability of this approach in combating MDR bacterial infections.
